Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/MD.0000000000011184 http://scihub22266oqcxt.onion/10.1097/MD.0000000000011184 C6024028!6024028 !29924035     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29924035 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Medicine+(Baltimore) 2018 ; 97 (25 ): e11184 Nephropedia Template TP {{tp|p=29924035 |t=2018. A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up |pdf=|usr=}}{{29924035 }} gab.com Text A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up JO: Medicine (Baltimore) http://www.kidney.de/pget.php?&tw=1&pmid=29924035 #FOAvip RATIONALE: As suggested by the 2012 KDIGO guidelines, persistent elevation of serum creatinine >?3.5?mg/dl (>?309??mol/l) (or an estimated glomerular filtration rate <?30?ml/min per 1.73?m is one of contradictions for the use of immunosuppressive therapy in membranous nephropathy. PATIENT CONCERNS: A 45-year-old man with membranous nephropathy negative for serum anti-phospholipase-A2-receptor antibody, showed no response to corticosteroids and cyclophosphamide. He progressed to chronic kidney disease stage 4 (CKD4) under tacrolimus and relapsed after withdrawal. DIAGNOSES: The patient received repeated renal biopsy, comfirming the diagnosis of membranous nephropathy with progressive glomerular and tubulointerstitial scarring. INTERVENTIONS: He was treated with successfully four times with lose-dose (180?mg/m every 2-3 months) rituximab (RTX) depending on his B cell counts, aiming to remain at 0-5?cells/?l. OUTCOMES: The patient was followed-up for almost 6 years. He achieved a partial remission at 11 months and a complete remission of the nephritic range of proteinuria at 34 months following infusion of RTX. RTX was well tolerated and the patient's renal function improved. He had no edema and his dosage of corticosteroids could be discontinued. LESSONS: This case strongly suggested that rituximab has promising therapeutic significance, even in patients progressing to CKD4. Twit Text FOAVip A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up ????Medicine (Baltimore) http://www.kidney.de/pget.php?&tw=1&pmid=29924035 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29924035 #FOAvip English Wikipedia <ref>{{Cite pmid|29924035 }}</ref> A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up #MMPMID29924035 Zhou XJ ; Zhou FD ; Wang SX ; Zhao MH Medicine (Baltimore) 2018[Jun]; 97 (25 ): e11184 PMID29924035 show ga RATIONALE: As suggested by the 2012 KDIGO guidelines, persistent elevation of serum creatinine >?3.5?mg/dl (>?309??mol/l) (or an estimated glomerular filtration rate |Follow-Up Studies [MESH] |Glomerular Filtration Rate/drug effects [MESH] |Glomerulonephritis, Membranous/blood/complications/*drug therapy/pathology [MESH] |Humans [MESH] |Immunologic Factors/therapeutic use [MESH] |Kidney/*pathology/physiopathology [MESH] |Male [MESH] |Middle Aged [MESH] |Proteinuria/drug therapy [MESH] |Receptors, Phospholipase A2/blood [MESH] |Remission Induction [MESH] |Renal Insufficiency, Chronic/classification/*drug therapy [MESH] |Rituximab/administration & dosage/*therapeutic use [MESH]A case report of remission of refractory membranous nephropathy progre(epmc).pdf DeepDyve Pubget Overpricing